Please ensure Javascript is enabled for purposes of website accessibility

Pfizer Can Now Vaccinate Teens. Will This Boost Orders?

By Adria Cimino – Updated Jun 23, 2021 at 7:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

We may see the impact a year from now.

The U.S. Food and Drug Administration (FDA) recently authorized the use of Pfizer's (PFE -0.91%) coronavirus vaccine in teens. In this Motley Fool Live video recorded on May 28, 2021, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss what this new authorization means for the company's revenue now and over time.

Olivia Zitkus: How about we turn to Pfizer. There has been a good bit of news there too. I think they reported in between the last time you were on as well and they just earned an expanded authorization for their vaccine to kids. It was May 10th. The FDA announced the expanded authorization for kids 12-15, previously it had been 16 and up. What does that mean for revenue for Pfizer? Is that a game-changer this year and the future? What are you thinking there?

Adria Cimino: Well, I think that first of all looking at this year, this doesn't mean new orders for this year. Because basically, the teens are going to get shots from today's supply because it's the same dose. It's the same vaccine. It's not like they're going to have to produce more and countries will have to order more. It doesn't really represent anything new for this year. I think that it could mean bigger orders in the future because now countries will see we can vaccinate a larger number of people, we can vaccinate teenagers and adults with this vaccine, so maybe we need to get a few more in stock. So it could mean larger orders in the future. As far as being a game-changer, I think probably not because there are other rivals there that are on the horizon. Unless rivals stumble. In that case, then it could be big. But otherwise, I would say not really.

Adria Cimino has no position in any of the stocks mentioned. Olivia Zitkus has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.76 (-0.91%) $0.40

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
104%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.